Welcome to our dedicated page for INVITAE news (Ticker: NVTAQ), a resource for investors and traders seeking the latest updates and insights on INVITAE stock.
Invitae Corp, traded as NVTAQ, is a renowned medical genetics company specializing in delivering timely genetic information using digital technology. With a mission to offer accurate and actionable answers, they aim to bolster medical decision-making through comprehensive genetic data. Invitae is a trusted name in mainstream medicine, dedicated to improving healthcare for millions worldwide.
Labcorp (NYSE: LH) has completed its acquisition of select assets from Invitae (OTC:NVTAQ), a leading medical genetics company. This strategic move extends Labcorp's leadership in genetic testing solutions, particularly in oncology and select rare diseases. The acquisition aims to enhance Labcorp's specialty testing capabilities and improve its ability to utilize genetic data in clinical trials and treatment regimens.
By integrating Invitae's genetic testing technology with Labcorp's existing capabilities, the company will offer more comprehensive insights for patients, from testing to diagnosis and treatment. This collaboration is expected to support patients, clinicians, and pharmaceutical partners across the continuum of care, including therapy development, patient diagnosis, and personalized care.
Invitae (OTC: NVTAQ) has launched the Unlock™ Behind the Seizure® program, offering accessible and affordable genetic testing for pediatric epilepsy patients under 18. The program aims to shorten the diagnostic process and enable personalized care. Genetic testing is recommended for unexplained epilepsy cases, as over half of epilepsies have genetic causes.
Invitae's epilepsy panel has shown a 1.4-fold higher rate of findings impacting disease management compared to exome tests. In a clinical study, 67% of patients with positive genetic test results experienced reduced or eliminated seizures when treatment was adjusted based on the results. The program also contributes to Invitae's rare disease database, aiding in drug discovery and clinical trial connections.
Invitae (OTC:NVTAQ) will present eight studies at the 2024 ASCO Annual Meeting in Chicago from May 31-June 4. The research underscores the importance of genetic testing for various cancers, including gastric, lung, prostate, and breast cancers. Key findings include:
- 13.4% of 3,706 gastric cancer patients had pathogenic variants.
- 12.6% of 14,317 lung cancer patients had germline variants, independent of smoking history.
- Genetic testing in 15,000 prostate cancer patients revealed significant findings even without family cancer history.
Studies also emphasize the need for genetic testing in underrepresented populations, with 18.3% of female breast cancer patients in Rwanda having pathogenic variants. Another study found that variants of uncertain significance (VUS) do not lead to overuse of treatment in breast cancer patients.
Labcorp (NYSE: LH) has received court approval to acquire assets of Invitae (OTC:NVTAQ), a leading medical genetics company, for $239 million in cash and non-cash consideration. The acquisition will advance Labcorp's specialty testing strategy in areas like oncology and rare diseases. The transaction is expected to enhance patient care, provide insights into health, and support clinical trials and treatment regimens.
FAQ
What is the current stock price of INVITAE (NVTAQ)?
What is the market cap of INVITAE (NVTAQ)?
What is the core business of Invitae Corp?
How does Invitae Corp aim to improve healthcare outcomes?
What sets Invitae Corp apart in the medical genetics field?
What is the significance of Invitae Corp's digital technology?
What makes Invitae Corp a leader in genetic testing services?
